EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

Guidelines for outpatient administration of naxitamab: Experience from Atrium Health Levine Children's Hospital

Erin Murphy Trovillion iD, Meghan Michael, Cathryn C Jordan, Lauren Brown, Katlin Phillips, Javier Oesterheld, Giselle Saulnier-Sholler iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.7045 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Erin Murphy Trovillion und 6 weiteren Autor:innen. Beteiligte Einrichtung: Atrium Health Levine Children's Hospital, Charlotte, North Carolina, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Neuroblastoma, Glycolipids, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

In this publication, we will share our experience of AE management, provide guidance for appropriate staffing, and the discuss the importance of patient education when treating patients with R/R HR neuroblastoma using naxitamab.

Background

Approved treatments for patients with refractory and/or relapsed (R/R) high‐risk (HR) neuroblastoma are limited, and there is a high unmet need for new treatment combinations. Naxitamab is a disialoganglioside 2 (GD2)‐binding antibody that was approved by the United States Food and Drug Administration in 2020 for use in combination with granulocyte–macrophage colony‐stimulating factor for the treatment of patients with R/R HR neuroblastoma in the bone and/or bone marrow and who have demonstrated a partial response, minor response, or stable disease with prior therapy.

Methods

The pediatric oncology team at Atrium Health Levine Children’s Hospital has successfully treated several patients with naxitamab both alone and in combination with chemotherapy, with no patients requiring unplanned overnight hospitalization and few severe adverse events (AEs). To accomplish this, the team at Levine Children’s Hospital established standard operating procedures for naxitamab, a therapy defined as high acuity due to the potential for acute AEs with rapid onset and that benefits from continuous monitoring by a nursing team and a dedicated provider.

Conclusions

This will provide a practical guide for institutions offering naxitamab to their patients, and ensure successful administration of this high acuity treatment in the outpatient setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalNeuroblastomaGlycolipidsAntibodies, Monoclonal, HumanizedChildHumansOutpatientsHospitals

Stichwörter der Autor:innen

immunotherapynaxitamabneuroblastoma

Substanzen

naxitamabAntibodies, MonoclonalGlycolipidsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Atrium Health Levine Children's Hospital, Charlotte, North Carolina, USA.

ORCID-Profile: Erin Murphy Trovillion, Giselle Saulnier-Sholler

Zitieren

APA

Trovillion, E. M., Michael, M., Jordan, C. C., Brown, L., Phillips, K., Oesterheld, J., & Saulnier-Sholler, G. (2024). Guidelines for outpatient administration of naxitamab: Experience from Atrium Health Levine Children's Hospital. Cancer Medicine. https://doi.org/10.1002/cam4.7045

Vancouver

Trovillion EM, Michael M, Jordan CC, Brown L, Phillips K, Oesterheld J, et al. Guidelines for outpatient administration of naxitamab: Experience from Atrium Health Levine Children's Hospital. Cancer Medicine. 2024. doi:10.1002/cam4.7045

BibTeX
@article{Trovillion2024,
  author = {Trovillion, Erin Murphy and Michael, Meghan and Jordan, Cathryn C and Brown, Lauren and Phillips, Katlin and Oesterheld, Javier and Saulnier-Sholler, Giselle},
  title = {Guidelines for outpatient administration of naxitamab: Experience from Atrium Health Levine Children's Hospital},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.7045}
}
Kostenlos starten →